[Electronic distribution for GENA by AEGIS/San Juan 714.248.2836]

 Volume 8 no. 4

 Gay Men's Health Crisis: Treatment Issues 

 > Cover letter
 > The ICC's New Combo Trials
 > Commentary: Another Day, Another Trial
 > The Torturous Development Path of Alpha-Thymosin
 > Delavirdine Enters Efficacy Trials
 > Highlights from the Fourth European Conference on AIDS
   >> New Diagnostic Techniques for Cytomegalovirus Infections
   >> Oral Ganciclovir To Prevent Cmv Retinitis Recurrence
   >> Famciclovir for Herpes Zoster
   >> Toxoplasmosis Suppression
   >> European Tuberculosis Studies
   >> Visceral Leishmaniasis
   >> Terbinafine for Nail Fungal Infections
   >> Aspergillus Infections Associated with Hospital Renovation
   >> Vitamin B12 and Folate Supplements
   >> Zinc and Opportunistic Infections
   >> Clotting Disorders in HIV-Positive Patients
 > Drug company watch 
   >> SmithKline Blocks Investigation of AIDS Drug
   >> First Human Data on Effectiveness of Antisense Drugs
   >> First U.S. HIV Antisense Trial Starts
   >> Bristol Meets with Activists on d4T 
   >> Viagene Begins New Gene Therapy Trial
   >> Lilly Leaves HIV Research
   >> Price Competition for Acyclovir (Zovirax)
 > Treatment Briefs 
   >> Oral Ganciclovir Access Plan (Sort of)
   >> Hyperthermia Trial to Start
   >> Pentoxifylline: Disappointing Data and a Warning
   >> Hydrogen Peroxide Therapy
   >> Poppers and the Immune System
   >> New Drug Tested for Genital Warts
   >> Depression and HIV
   >> Correction


 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^

 [Cover letter]

 Dear readers:

Your subscription payments, renewals and generous 
contributions have enabled us to provide vital treatment 
information to people all over the world. It has made 
possible our advocacy work aimed at creating a more 
proficient and productive HIV/AIDS research effort. If you 
have not yet renewed your subscription or are able to make 
another donation, please complete the form below and return 
it to us in the enclosed envelope. Your continuing support 
means a great deal to us.

We would like to take this occasion to bring you up to date 
on Treatment Issues and the work of the new Treatment 
Education and Advocacy Department at Gay Men's Health Crisis:
GMHC has reorganized its treatment education program. In 
January of this year, Jeff Richardson, the Executive Director 
of GMHC, created a new Department of Treatment Education and 
Advocacy (TEA) in order to expand GMHC's impact on national 
and corporate HIV/AIDS research policy. TEA also will broaden 
GMHC's treatment education programs to ensure that people 
with AIDS and their care providers have access to the best 
information possible when making difficult treatment 
decisions. The new department is headed by David Barr, 
formerly of the GMHC Policy Department.

We are committed to providing objective HIV treatment 
information and making Treatment Issues available to whomever 
needs it. Treatment Issues remains the centerpiece of GMHC's 
treatment information program. The newsletter neither accepts 
nor solicits money from drug companies or government 
agencies. Since we began publishing in 1987, everyone who has 
requested a subscription to Treatment Issues has received one 
regardless of his or her ability to pay. Our monthly 
circulation of over 20,000 includes individuals and 
organizations from all over the world - North and South 
America, Europe, Asia, Africa and Australia. Our articles are 
reprinted in hundreds of other community publications.

We are planning more special editions of Treatment Issues. We 
published a 32-page special edition of TI devoted to 
"Alternative Therapies for HIV" as well as a special edition 
on the Concorde Study results concerning early intervention 
with AZT. In the coming year, we are projecting special 
editions devoted to "Current Standards of Care for HIV," 
"Therapies for Advanced HIV Disease" and a complete glossary 
for TI readers.

We also are expanding Treatment Issues. Treatment Issues has 
been expanded in both size and frequency. We now publish 
monthly instead of nine times per year. We often publish 16 
page editions in order to provide more information to our 
readers. Last year such features as Washington Watch, Drug 
Company Watch, the TI Interview, editorials, and commentaries 
all began making regular appearances in TI. We now are 
considering adding other columns that would make TI a more 
accessible publication.

We are introducing a series of Treatment Issues fact sheets. 
This month we will publish the first set in a series of 
"Basic Fact Sheets" on HIV-related opportunistic infections. 
They will appear in both English and Spanish These fact 
sheets will present information in a simple, easy-to-read 
format. We also will be offering "In-Depth Fact Sheets" that 
enable readers to obtain all the information ever published 
in Treatment Issues on any specific HIV-related therapy or 
condition. These fact sheets will significantly improve our 
ability to respond to requests for information from the 
public.

Our "Treatment Forums" series is providing the community with 
a wide range of up-to-date information. Over the last year we 
have put together a regular series of community treatment 
forums to increase awareness of state-of-the-art medical 
therapy and focus attention on promising areas of AIDS 
research. These forums have covered such topics as long-term 
survival, future directions in the treatment of Kaposi's 
sarcoma, alternative therapies for HIV, risk of HIV 
transmission through oral sex, reports from the IX 
International Conference on AIDS, and prevention of 
opportunistic infections. We have initiated regular treatment 
forums in Spanish, too. Both the English and Spanish forums 
are presented in collaboration with many other AIDS 
organizations, including the Community Research Initiative on 
AIDS, Treatment Action Group, Latino AIDS Treatment Issues 
Group, Latino Commission on AIDS, Elmhurst Hospital and 
Columbia University. Tapes and summaries of many of these 
forums are available to TI readers. 

Our Treatment Library continues to grow. The GMHC AIDS 
Treatment Library has enlarged its size and scope. It is now 
open to the public four days a week from 10 a.m. to 1 p.m. 
and provides Medline and AIDSline computer services, the 
latest medical journals, newsletters, reference materials and 
our comprehensive files on all medical aspects of HIV/AIDS. 
The library has received substantial donations from a number 
of publishing companies and has become a member of the 
prestigious METRO Medical Network made up of New York area 
hospital and university medical libraries. 

In an effort to use our resources even more effectively, we 
have reduced our printing and mailing costs substantially in 
the course of the past year. Nevertheless, your continuing 
support is essential to our expanding effort. Please take a 
moment of your time to send us a renewal or contribution with 
the form below. Note that, as always, all Treatment Issues 
subscription lists are kept strictly confidential. We do not 
even allow them to be part of the general GMHC mailing lists.
Thank you in advance for your assistance. We would appreciate 
any comments you might have as to how we could better fulfill 
our goals. A business reply envelope is enclosed for your 
convenience.

 David Gold, Executive Editor ; Dave Gilden, Editor; Gabriel 
Torres, M.D., Medical Consultant; Paul Warren, Technical 
Coordinator

 [GMHC
  129 W. 20th Street
  New York, NY 10011]

 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

The ICC's New Combo Trials
 by Derek Link 

The Inter-Company Collaboration for AIDS Drug Development 
(popularly known as the ICC), a private consortium that 
includes sixteen major drug companies involved in AIDS 
research, announced its "master protocol" for triple-drug 
combination therapy to a meeting of activists in New York on 
April 26. According to its chief architect and proponent, Dr. 
David Barry of the Burroughs Wellcome Company, the master 
protocol is designed to find a "home-run" triple drug 
combination that for 52 weeks restores CD4 cell levels back 
to an immunologically normal state (above 800 cells/mm3 of 
blood) and eliminates detectable viral replication. The 
study's sponsors do not plan to collect clinical data (such 
as symptoms and disease progression) on study participants.

The plans for the trial were greeted with substantial 
criticism by the activists in New York, many of whom regarded 
the potential for finding a "home-run" treatment from any of 
the proposed combinations as negligible. The critics 
questioned whether the trials would produce meaningful data 
to clearly determine whether any of these combinations have a 
more modest benefit in treating HIV infection.

Trial Design

The protocol, designed as a pilot study, will enroll 100 
asymptomatic patients with 200 to 500 CD4 cells and no prior 
HIV treatment in each study arm. The study will sequentially 
enroll patients. The first 100 patients will receive the 
first combination regimen, the next 100 patients will receive 
the second regimen, and so forth. The ICC initially will use 
two approved drugs and one unapproved drug to create the 
three-drug combinations.

The ICC will begin with four triple-drug regimens, enrolling 
patients at "10 to 20" sites nationwide. Sites have not yet 
been selected, but accrual could begin sometime this summer. 

The four regimens selected for earliest evaluation are:
 Arm 1: AZT + ddC + Saquinavir (the Roche protease inhibitor)
 Arm 2: AZT + ddI + Nevirapine
 Arm 3: AZT + ddI + 3TC
 Arm 4: AZT + ddC + Nevirapine

All drugs will be used at standard monotherapy doses. Dr. 
Barry anticipates that accrual into each regimen will take 
two to three months. If a "home-run" effect occurs, it could 
be noted as early as 26 weeks into the study because regular 
interim analyses are planned. 

Although the ICC hopes to score a home-run with this 
strategy, it recognizes that a less dramatic therapeutic 
effect may also occur. Thus a graded scale has been developed 
to record a range of therapeutic responses that fall short of 
a home run. Four types of response will be examined: 
immunological markers, HIV levels, adverse effects and 
emergence of drug-resistant HIV strains. Each of these areas 
will be graded. For immunological markers, a "Grade A" 
response is CD4 cells returning to normal (above 800) in 90 
percent of patients. A "Grade D" response is no CD4 effect at 
all.

Criticisms of the Trial Design

The first criticism of this trial design concerns 
randomization, the process by which patients in a clinical 
trial are "randomly" assigned to different treatments. 
Randomization minimizes the differences among groups by 
equally distributing people with particular characteristics 
among all the arms. It also allows for certain statistical 
methods to be applied to the data.

But the ICC master protocol is not randomized. The failure to 
randomize the study means that the data generated by it will 
lack both confidence and sophistication. It may be open to 
substantial bias if the different groups do not have 
equivalent characteristics that affect their response to 
therapy.

Then too, the study has no "control arm" (e.g. a placebo or 
even a standard therapy regimen) against which the effect of 
triple-drug combination is compared. Instead, the master 
protocol will compare triple-drug combination to an 
historical control - i.e., surrogate marker data from 
similar patients in previous studies.

Historical controls do have some advantages. Fewer patients 
are required for a study, resulting in easier recruitment. 
The trials also are much cheaper and simpler to conduct.
Historical controls have some significant disadvantages, 
though. In the specific case of anti-HIV therapies, little is 
known about two-drug combination therapy in patients who have 
never before taken anti-HIV drugs. It is hard to imagine how 
the ICC can arbitrarily establish standard comparison data 
for this patient group. Not only are immunological markers, 
such as CD4 cell counts, open to considerable uncertainty for 
these people, but the effect of antiviral drugs on newer 
virological markers (like PCR or branched-chain DNA assay) 
has not been established.

In general, trials utilizing historical controls tend to 
over-estimate the therapeutic effect of treatment. 
Uncontrolled studies generally yield a much higher percentage 
of positive results than controlled studies.[1,2]
All criticisms of the trial are not scientific. Only 
"nucleoside analog naive" volunteers (no history of taking 
AZT, ddI, ddC, etc.) are eligible for the study, which raises 
a difficult issue. People who have faithfully followed 
government, industry and (in some cases) community 
recommendations that "it's never too early" to start 
nucleoside analog treatment now find that the presumed 
cutting edge of research is unavailable to them. Is this 
anyway to treat one's best customers?

The most significant criticism of the trial is the drugs 
themselves. Three of the four regimens selected for initial 
investigation include only reverse transcriptase inhibitors, 
with the combination of AZT, ddI and 3TC being particularly 
dubious. Few virologists believe that a "home-run" is 
possible with a regimen that includes just reverse 
transcriptase inhibitors or even any of the drugs currently 
available. The trial appears in some respects to be a renamed 
repeat of the notorious "convergent combination therapy."
The obvious, sad reality is that there are few new drugs to 
plug into the master protocol. This situation underscores the 
desperate need for new agents. Accordingly, the ICC must open 
up membership to the biotechnology industry, which is at the 
cutting-edge of drug discovery.

Strengths of the Trial

The master protocol has some important strengths that should 
not be overlooked. For treatment-naive asymptomatic patients, 
this trial represents a new option that some may find highly 
desirable. Despite the study design's scientific weaknesses, 
the protocol is probably adequate to detect a "home-run" 
treatment. A dramatic "cure," a treatment that brings 
patients back to normal and eliminates viral replication, is 
not difficult to observe. The problem, of course, is that 
treatments up to now have not shown such a dramatic, 
overwhelming effect. 

The ICC protocol is a good sign that the drug industry is 
serious about cooperation. By explicitly going after a home-
run strategy, the industry also has taken an important step 
toward defining its role in clinical research of HIV disease. 
Up to this point, no research group (government, industry or 
academic) has so clearly defined its mission. One hopes that 
other organizations, particularly those that are publicly 
funded, will follow the ICC's example and clarify their own 
missions. 

And here's a final point not to be dismissed lightly: ICC 
members are spending their own money on these trials.

1 Sacks H, et al. American Journal of Medicine, 1982; 
72(2):233-40.

2 Sacks H, et al. Archives of Internal Medicine, 1983; 
143(4):753-5.


 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

Commentary: Another Day, Another Trial
 by Dave Gilden and David Gold

Low dose oral alpha interferon (LDAI) - including Kemron and 
similar products - attracted a great deal of attention almost 
five years ago when Davy Koech, M.D., of Kenya announced a 
stunning reversal of the AIDS disease process in patients who 
let lozenges containing the substance dissolve in their 
mouths. Dr. Koech also claimed a series of controversial 
"serodeconversions," in which HIV-positive patients became 
HIV antibody-negative after Kemron therapy. Not surprisingly, 
these results received widespread publicity, creating 
significant demand for oral alpha interferon at AIDS buyers 
clubs, and even a number of physicians began selling various 
oral alpha interferon products.
In 1992, the National Institute of Allergy and Infectious 
Diseases (NIAID) reviewed thirteen different LDAI studies 
here and abroad. The Institute concluded, "The initial claims 
which have been made on behalf of Kemron ... have not been 
confirmed.... People with HIV infection will be best served if 
they receive treatments which have been shown efficacious in 
well controlled studies."[1]
At the 1993 International Conference on AIDS, Elly Katabira, 
M.D., of Uganda announced the results of a 560-person 
placebo-controlled trial.[2] The study, which was sponsored by 
the World Health Organization, found no difference between 
Kemron and the placebo. There was no evidence of any effect 
on CD4 cells, viral load, disease progression, survival or 
"quality-of-life" indicators. 

Nevertheless, officials at NIAID, the division of the 
National Institutes of Health (NIH) that receives almost half 
of all U.S. government AIDS research dollars, are proceeding 
with plans for another large oral alpha interferon trial. 
Taking the lead in planning and funding the study is the 
Community Programs for Clinical Research on AIDS (CPCRA), a 
unit of NIAID. 

Why Another Trial?

Even those planning the study do not believe that oral alpha 
interferon works. Dr. Lawrence Deyton, Director of the CPCRA, 
readily admits that "scientific evidence proves [the LDAI] 
products give no benefit in fighting HIV or in improving the 
immune system of persons with HIV infection."[3] Why then 
proceed with an expensive new test that only prolongs 
uncertainty over the substance? Dr. Deyton argues that 
continued community use of LDAI, particularly in the African-
American community, requires yet more definitive testing of 
the substance.

Why not just publicize the results of the WHO/Ugandan study 
then? "We accept the immunological and virological data from 
the WHO/Ugandan study," Deyton told Treatment Issues, "but 
the quality of life issues are clouded. The Ugandan people 
were very sick to start with." Additionally, deficient care 
may have obscured the results. The new LDAI trial will 
primarily investigate whether the therapy causes any 
reduction in clinical symptoms related to the HIV-associated 
decline in immunity.

Small trials in Los Angeles and New York did find some slight 
symptomatic relief, mainly in terms of restored energy and 
weight. But with enough studies, some positive data will 
always appear, just from random variation. These results are 
specifically countered not by just the WHO/Ugandan study, but 
by a trial conducted through the Community Research 
Initiative of Toronto in 149 HIV-positive individuals,[4] in 
addition to all the other oral alpha interferon studies that 
found no significant effect from the drug.

Most researchers do not believe that oral alpha interferon 
can have any effect because the interferon protein is broken 
down and rendered useless by fluids in the stomach. That is 
why all interferons approved for therapeutic use are injected 
subcutaneously (into the skin). The conjecture that alpha 
interferon directly affects immune cells in the mouth and 
sparks an improvement in immune system responsiveness remains 
highly speculative with no supporting data. 

Wasting Precious Dollars and Goodwill

The new trial, which will enroll 800 people and compare three 
versions of LDAI, is to begin later this year. The cost of 
the study may be in the millions (not including the cost of 
NIAID staff time in planning and overseeing the trial). Dr. 
Deyton claims the cost will be less, but refused to be quoted 
on a specific figure. 

In addition, the smaller and more difficult a drug's benefit 
is to measure, the larger and more extensive a clinical trial 
must be to document that benefit. There is no reasonable 
assurance that this trial will prove large enough to show any 
quality-of-life benefits from the drug. Failure of this trial 
to document an effect from LDAI may only elicit calls for 
another, still larger trial.

Besides consuming valuable research funds and staff time, the 
proposed trial will waste human resources. People who enroll 
in a clinical trial are contributing the most valuable thing 
they have - their bodies. It is unconscionable to enroll 
people in a clinical trial, particularly one sponsored by the 
U.S. government, when there is no reasonable evidence that 
the therapy being tested is of benefit. Individuals 
participating in this study may forego other therapeutic 
options, or render themselves ineligible for more appropriate 
clinical trials. They also may become further disenchanted 
with the clinical trial system when the false hopes played 
upon to draw them into the trial are dashed.

Rather than improve relations between the scientific and 
African-American communities through this trial, as has been 
hoped, the gap between the two may only grow more 
insurmountable.

Making Sense of Research Priorities

Many observers, including The New York Times, report that 
LDAI is being kept alive by political pressure, especially 
from medical clinics connected with the Nation of Islam, 
which has helped popularize LDAI in the African-American 
community.[5] But LDAI has also received support from the 
National Medical Association, the well-established 
organization of African-American physicians in the United 
States.

The chair of the LDAI protocol team, Lawrence Brown, M.D., of 
Brooklyn argues, "Things are not driven by pure science, 
there's politics on all sides: Who believes in what data? 
Look at all the effort put into AZT, and with such little 
yield."

Dr. Brown is exactly right. Too much government funding has 
gone towards studying AZT and its sister drugs, ddI and ddC 
(although these drugs at least can reduce viral load and 
provide modest increases in CD4 levels - oral alpha 
interferon does neither). Let's not do the same with LDAI, 
while leaving promising experimental therapies and areas of 
basic virological and immunological research starved for 
funds. LDAI keeps reappearing precisely because the medical 
establishment has nothing really effective to offer people 
with HIV - especially those in disenfranchised and poor 
communities, who have the least access to care and promising 
therapies.

The LDAI saga sums up much of what is wrong at NIAID: endless 
trials of mediocre drugs without any clear insight into what 
strategies could yield effective therapies and an all too 
pervasive acceptance of wasteful and redundant clinical 
studies. Let people take Kemron - if they want it. NIAID 
resources should be used for more productive lines of 
research.

This is the first in a series of commentaries that will 
appear in Treatment Issues on AIDS research at the NIH.

1 National Institutes of Health. Interim Report: Low-dose 
oral interferon alpha as a therapy for human immunodeficiency 
virus infection (HIV-1): completed and on-going clinical 
trials. April 1992.

2 Katabira E, et al. IX International Conference on AIDS, 
1993; abstract PO-B26-2056.

3 Deyton L. Letter to CPCRA Steering Committee. October 5, 
1993.

4 Hulton, MR et al. Journal of Acquired Immune Deficiency 
Syndromes, 1992; 5(11):1084-90.

5 The New York Times. March 4, 1994.

 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

The Torturous Development Path of Alpha-Thymosin
 by Dave Gilden and Jay Levin

One of the great hurdles that any anti-HIV drug must overcome 
is the lack of a persistent immune response that combats HIV. 
A successful antiviral treatment will have to clear the virus 
from the body in the face of an increasingly dysfunctional 
immune system.

A number of immune modulators have been tested in conjunction 
with anti-HIV drugs in an attempt to improve the immune 
response. Yet, results have been inconclusive and the side 
effects often severe. Recently, a small, unblinded Italian 
study reported that a substance known as alpha-thymosin 
(thymosin), when used in combination with alpha-interferon 
and AZT, provided more sustained increases in CD4 cells than 
AZT alone.

Just announced results from another, larger study of thymosin 
suggest that the drug is not effective as a treatment for 
chronic hepatitis B, however. The question now is whether 
Alpha 1 Biomedicals, the small, underfunded biotech firm 
developing thymosin, has the resources to mount new, 
redesigned trials. 

Natural Thymic Hormones

The thymus gland has been identified as a key immune system 
organ. It is thought to be responsible for the development 
and regulation of the immune system cells that mature in that 
organ (such "T-cells" as CD4 helper cells and CD8 cytotoxic 
cells). The thymus seems to exert its regulatory functions 
through the secretion of various hormone-like products called 
thymic peptides. Although the importance of thymic peptides 
remains in dispute, several investigators have reported that 
thymic peptide products can assist development of immature, 
precursor cells into fully competent T-cells. They also 
regulate the functioning of T-cells once they have matured.

Alpha-thymosin is a thymic peptide that adjusts an 
individual's immune responsiveness when aberrations occur. 
Thymosin boosts the number of receptors on T-cells, 
especially for alpha-interferon and IL-2. It also increases 
the efficiency of T-cells' response to signaling agents and 
causes cells to produce more of them.[1]

Intercellular signaling molecules ("cytokines") like alpha-
interferon and IL-2 commonly have severe adverse effects. 
These agents are released during disease to help bolster the 
inflammatory response, which causes a variety of flu-like 
symptoms. Thymosin, in contrast, circulates in the blood at 
comparatively constant levels. In a series of clinical trials 
involving a total of nearly 1,000 people, no serious side 
effects have been noted.[1] Since thymosin promotes the action 
of alpha-interferon and IL-2, combining it with these 
products could allow lower dosages to be used, resulting in 
both greater safety and more efficacy.

Thymosin in HIV

This year, an Italian research group led by Enrico Garaci 
published encouraging results from a small trial comparing 
various combinations of thymosin, alpha-interferon and AZT in 
people with HIV.[2] The trial enrolled 40 HIV-positive men and 
women with CD4 cell counts of 200 to 500 per cubic milliliter 
of blood and without previous treatment for HIV infection. 
(The trial was randomized, but unblinded - everybody 
involved knew who was receiving which treatment.) 
Unfortunately, the dropout rate in this already small trial 
was high: by the end of twelve months, only 28 patients were 
available for evaluation, and by eighteen months only 23 
remained.

Trial volunteers were assigned to one of four groups. The 
first received 500mg of AZT twice daily. The second group 
received AZT plus two million units of natural human alpha-
interferon twice weekly, and the third group received AZT 
plus 1mg thymosin subcutaneously twice weekly. The fourth 
group had the complete combination - AZT, thymosin and 
alpha-interferon.

Over the first ten months, CD4 counts rose by an equivalent 
amount in the AZT plus interferon group and in the triple 
combination group. In the AZT only group and the AZT plus 
thymosin group, CD4 counts fell or were stable, respectively. 
But then CD4 counts in the AZT plus interferon group on 
average dropped back to baseline whereas the triple-drug 
people saw their CD4 counts continue to rise. At twelve 
months, the average increase amounted to 187 CD4 cells per 
cubic millimeter of blood. At eighteen months, the average 
increase was 237 CD4 cells while the counts for the other 
three treatment groups were close to the original, baseline 
averages.

The small size and high drop-out rate of this trial make it 
difficult to have confidence in these results. Those who 
discontinued were not followed, and without this data, it is 
difficult to draw even tentative conclusions. Be that as it 
may, the Italian government subsequently funded a much 
larger, more definitive trial of the thymosin-interferon-AZT 
regimen. This 100-person study is now two-thirds enrolled. 
Investigators will present an update on this trial at the 
"Fourth International Conference on Combined Therapies," to 
take place next month in Sardinia, Italy. No confirmed data 
is available at present from this trial.

The investigators hope to release preliminary data on the 
first six months of treatment by the end of the year. 
Measurements will include assays of CD4 and CD8 counts, HIV 
p24 antigen, beta2 microglobulin (an index of immune 
activation), HIV levels in the blood, and a lab test for 
immune cell proliferation response. Crucial clinical data on 
the rate of opportunistic infections also will be available. 
(A reduced rate of opportunistic infections would confirm 
that the improvements seen in laboratory tests, if any, 
actually have functional value in improving people's health.)

A Disappointing U.S. Trial for HIV

Thomas Merigan, M.D., the director of the Center for AIDS 
Research at Stanford University, has been conducting an 
initial study of thymosin combined with PEG IL-2 (IL-2 joined 
to polyethylene glycol for increased stability) and AZT. Dr. 
Merigan, who has studied IL-2 for some years with 
disappointing results, says, "Thymosin has had some 
interesting results in Italy and with hepatitis [see below]. 

The point of this trial is to see how thymosin boosts the 
effect of IL-2 in patients with 50 to 200 CD4 counts, where 
IL-2 just starts to have an effect." Merigan is following 
changes in trial participants' CD4 counts and HIV levels.

The fourteen volunteers for this study started out on AZT 
alone (500mg per day) for eight weeks. Then they went on AZT 
plus IL-2 (one million units per square meter of body surface 
every other week) for another eight weeks. In the final 
twelve weeks, an escalating dose of thymosin was added. 
Merigan will not yet comment on the results of this trial, 
which enrolled its first volunteer a year ago. (The final 
analysis of the data will not be available until late summer, 
he says.)

Several informed sources have told Treatment Issues, though, 
that the trial has not found any benefits from the triple 
combination regimen. Some suggest that the participants were 
not receiving thymosin long enough to make a difference or 
that, alternatively, since patients in the U.S. trial, who 
had more advanced disease than those in the Italian trial, 
may have been too sick for thymosin to have an effect. A 
final possibility is that thymosin plus IL-2 is just the 
wrong combination for fighting HIV.

Discouraging Results with Hepatitis B

In the United States, Alpha 1 Biomedicals has concentrated on 
developing the product for chronic hepatitis B, which affects 
at least 300 million people worldwide. Chronic hepatitis C is 
also under study.

Of course, a safe treatment for chronic hepatitis would be of 
great interest to people with HIV, many of whom are co-
infected with hepatitis B or hepatitis C. Progression of 
hepatitis disease may trigger progression of HIV or vice 
versa. Alpha-interferon, the only approved treatment for 
chronic hepatitis B, induces sustained disease remission in 
only 25 to 30 percent of those treated, and side effects 
often dictate stopping treatment.

Data from a phase II study of chronic hepatitis B suggested 
that thymosin might be a significant advance.[3] Nine of the 
twelve of the "thymosin treated" volunteers responded 
favorably to treatment, and seven (58 percent) had a 
sustained remission with normal liver tests and negative 
hepatitis B antigen status after four years.

However, recently announced results of a phase III, placebo 
controlled study indicate that thymosin was no better than 
placebo as a treatment for chronic hepatitis B. The 99 
patients in the study received either thymosin or placebo for 
six months, with another six months of follow-up. After one 
year, eleven of the 49 people in the thymosin arm tested 
negative for hepatitis B virus DNA, compared to twelve of 50 
people in the placebo arm.

Unraveling the Contradictions

The hepatitis B trial is extremely disappointing. The Italian 
group, meanwhile, is conducting a combined alpha-interferon 
plus thymosin study for hepatitis B and C in 30 people. 
Researchers are reporting high rates of remission, even in 
people who previously had not responded to interferon alone. 
Thymosin's main hope is now likely to be new trials using 
interferon and thymosin together.

But Alpha 1 may not be financially able to mount more trials, 
let alone large, definitive ones. The day the recent 
hepatitis B results were announced, Alpha 1 Biomedicals' 
stock fell by two-thirds.

The company has been further weakened by a dispute with the 
company's marketing licensee for outside North America and 
Europe, which is now before an arbitrator. That licensee, 
SciClone Pharmaceuticals, is demanding and may well get 
damages and greater rights to alpha-thymosin because Alpha 1 
has not been able to provide the drug due to a breakdown in 
the manufacturing agreement with a Belgian company. The 
damage award alone could bankrupt cash-starved Alpha 1. 

SciClone is moving aggressively to sell thymosin in Asia, 
which has an enormous population of hepatitis B carriers. 
(Thymosin is already approved in Singapore.) The day Alpha 
1's stock price fell, SciClone bought 15 percent of the 
shares, making it Alpha 1's largest shareholder. This only 
adds to the uncertainty concerning alpha-thymosin's future 
development.

Meanwhile, Alpha 1's Italian licensee, Sclavo, has been 
caught up in Italy's general financial scandal, and progress 
in bringing thymosin to market in Italy (where it is approved 
as a vaccine additive) has been retarded.

Because of these difficulties, thymosin is not available 
outside of clinical trials anywhere in the world, although 
Italian supplies are expected to exist eventually. Thymosin 
may soon appear in the U.S. underground market, too, but wide 
availability awaits future positive trial data. Lacking 
quick, convincing results from the Italian HIV trials, 
funding will be a serious problem.

Despite the problematic aspects of past thymosin trials, some 
believe that the drug merits further scientific attention. 
The Los Angeles-based Search Alliance wants to conduct a 
rigorous study combining AZT, alpha-interferon and alpha-
thymosin in HIV-positive individuals. 

Chuck Chesson, Search Alliance's clinical trial coordinator, 
says, "Thymosin results have been interesting. The question 
has to be answered - people need to know whether thymosin 
works or not."

Although Search Alliance is a community organization, the 
total cost of this medium-size trial still will amount to 
$200,000, not counting the cost of the medicine. Encouraging 
findings from this economical option (or the current Italian 
government funded HIV study) may offer thymosin its only 
chance for garnering the grassroots and financial support. 
Without that support, its continued development is 
questionable, regardless of the compound's value.

1 Goldstein, A. personal communication, April 24, 1994.

2 Garaci E, et al. International Journal of Clinical and 
Laboratory Research, 1994; 24(1):23-8.

3 Mutchnick MG, et al. In: Graci E and Goldstein AL. Combined 
Therapy: Biological Response Modifiers in the Treatment of 
Cancer and Infectious Diseases, 1992; Plenum Press.


 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

Delavirdine Enters Efficacy Trials
 by Gabriel Torres, M.D.

Delavirdine (also known as U-90152) is a new anti-HIV drug 
manufactured by Upjohn Company. It belongs to the class of 
compounds called non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). These compounds block HIV replication by 
inhibiting the same enzyme, reverse transcriptase, that is 
blocked by nucleoside analogs like AZT, ddI, ddC and d4T. 
NNRTIs strongly protect uninfected cells from HIV, but they 
have been plagued by HIV's ability to rapidly develop 
resistance to them.

It is hoped that delavirdine, when combined with other drugs 
such as AZT, ddI, other NNRTIs, or protease inhibitors, can 
slow down emergence of viral resistance. Precisely because of 
this resistance, delavirdine is unlikely to be effective as a 
single agent. Combining the drug with additional antiviral 
agents, though, might so reduce HIV replication that 
resistance to any of the components in the combined regimen 
will take much longer to evolve. Also, the development of 
resistance to delavirdine seems to increase HIV's sensitivity 
to other NNRTIs.

Delavirdine's long-term side effects still need to be 
evaluated, as does its activity during pregnancy. The 
influence of the drug on fetal development and its ability to 
reduce mother-to-child HIV transmission remain unknown.

Laboratory Studies

In the test tube, very low concentrations of delavirdine can 
totally stop HIV-1 from infecting new cells and causing cell 
death. It is also more potent than AZT and is effective 
against AZT- and ddI-resistant strains of HIV in the 
laboratory.[1] In AZT- or ddI-sensitive strains, delavirdine 
has been found to be synergistic with AZT or ddI (the effect 
of the combined treatment is greater than the sum of the 
individual drugs' effects).[2] The compound is synergistic with 
the first version (now canceled) of Upjohn's protease 
inhibitor, too.[3] Delavirdine can also reduce the formation of 
syncytia (clumping of cells which leads to rapid T cell 
destruction).[1]

Unfortunately, when delavirdine is introduced to HIV-infected 
cell cultures, viral strains that are ten- to 100-fold less 
sensitive to the drug emerge. This drug resistance is 
triggered by single changes (or point mutations) in the amino 
acid sequence of the reverse transcriptase enzyme. One such 
mutation (at amino acid number 236) causes high-level 
resistance to delavirdine but sensitizes the virus to other 
NNRTIs such as nevirapine, TIBO compounds and Merck & Co.'s 
L-drug (L-697). Yet, it does not change sensitivity to 
nucleoside analogs such as AZT and ddC.[4]

Animal Studies

Animal studies using delavirdine have focused on determining 
its toxicities and adverse effects. The lowest dose in 
animals in which notable toxicity has been observed is 50mg 
per kilogram of body weight per day. This dose produced 
inflammation of blood vessels (vasculitis) in dogs over a two 
week period. Higher doses caused gastrointestinal 
ulcerations, bone marrow toxicity and lung inflammation. The 
drug also led to birth defects in pregnant rats at extremely 
high doses. Since the drug is so potent, there is a wide 
margin of safety - low doses can be effective in achieving 
levels in the body that inhibit the virus.

Phase I Human Studies

Two clinical studies in normal healthy male volunteers have 
been completed. These placebo-controlled studies showed that 
the drug was tolerated in single doses of up to 300mg and 
multiple doses of up to 100mg four times daily without side 
effects; headache occurred frequently in both the delavirdine 
and placebo groups. Two multiple-dose safety, tolerance, and 
pharmacokinetic studies in 87 HIV-positive volunteers have 
been completed. It appears that the drug is well tolerated 
when given orally in amounts up to 400mg three times daily in 
combination with AZT and up to 300mg four times daily in 
combination with AZT and ddI. The most frequent side effect 
is a rash that appears after one week on the drug. The rash 
occurred in 27 percent of patients who took delavirdine in 
combination with AZT and in 38 percent of those who took it 
in combination with AZT and ddI. Most patients were 
subsequently rechallenged with a lower dose once the rash had 
resolved. They were able to tolerate their original assigned 
doses after two weeks on the lower dose. Increases in liver 
function tests occurred in two patients and resolved after 
all antiretroviral agents were discontinued. A new crystal 
form of delavirdine has also been developed by Upjohn that 
seems to be more heat-stable. The new form is being used for 
the large scale clinical trials initiated this spring. 

New Delavirdine Clinical Trials

Upjohn is launching three new clinical trials of delavirdine 
in multiple centers throughout the United States. The first 
trial is a double-blind randomized study of three doses of 
delavirdine in combination with AZT versus AZT alone.
The trial will measure delavirdine's efficacy based on 
changes in HIV viral load, CD4 cell counts, and disease 
progression. HIV-positive persons with CD4 cell counts of 200 
to 500 who have had less than six months of prior AZT therapy 
are eligible for this two-year trial. According to trial 
plans, 1,200 to 1,500 participants will be enrolled. It is 
hoped that women will make up 20 percent of the participants.
The delavirdine doses used will be 200, 300 or 400mg three 
times daily in combination with AZT at 200mg three times 
daily. The addition of ddI will be allowed in all treatment 
groups if a study participant experiences a fall in CD4 count 
to below 50 percent of baseline on two consecutive occasions 
or develops an AIDS-defining illness.

The study will exclude persons with previous ddI, ddC, 3TC or 
d4T therapy, patients unable to take AZT, and those who have 
received therapeutic vaccines. The use of drugs that can 
interact with delavirdine and lower its blood levels will not 
be allowed within 21 days of study entry. These include a 
large number of drugs used to treat opportunistic infections 
and other conditions, including ketoconazole, fluconazole and 
itraconazole for fungi; isoniazid and rifampin for 
tuberculosis, rifabutin for mycobacterium avium complex 
(MAC); and astemizole and loratadine, which are anti-
histamines.

A second parallel study will compare delavirdine in 
combination with didanosine (ddI) versus ddI alone. This 
trial will follow people with HIV who have CD4 counts less 
than 300 and previous experience on AZT but less than four 
months on ddI. Plans are to enroll between 800 and 950 
patients for a two-year time period.

This study, too, will exclude patients with prior ddC, d4T or 
NNRTI therapy. There is some concern that such people will 
develop HIV strains resistant to ddI in addition to ddC. This 
will be a problem for those in the ddI-only arm. The trial 
also will exclude patients requiring therapy with rifampin, 
rifabutin or the anti-histamine terfenadine (seldane).

Both studies will compare the emergence of drug-resistant HIV 
in patients on the delavirdine combinations versus those on 
nucleoside analog monotherapy. One interesting aspect of 
these studies is that they will also measure the cost-
effectiveness and quality of life effects of adding 
delavirdine to AZT or ddI monotherapy.

Finally, a third study is being conducted by Upjohn for 
patients who have participated in previous delavirdine 
studies. It will evaluate and compare the use of delavirdine 
in triple combination with ddI and AZT or ddC and AZT. This 
third trial is expected to enroll over 4,000 people. 

For information on the delavirdine trials contact 800/TRIALS-
A. A number of trial sites will be located in the New York 
area at various sites, including the Community Research 
Initiative on AIDS (contact Bette Smith at 212/924-3934), St. 
Vincent's Hospital (contact Daisy Soto, R.N., 212/604-8920), 
Beth Israel Medical Center (contact Carsandra Sanders, P.A., 
at 212/420-4519), Mt. Sinai Medical Center (contact Eileen 
Chusid, Ph.D., at 212/241-3933).

1 Dueweke TJ, et al. Antimicrobial Agents and Chemotherapy, 
1993; 37(5): 1127-31.

2 Chong KT, et al. Ninth International Conference on AIDS, 
1993; abstract PO-A25-0606.

3 Chong KT, et al. Ninth International Conference on AIDS, 
1993; abstract PO-A25-0557.

4 Dueweke TJ, et al. Proceedings of the National Academy of 
Science USA, 1993; 90(10):4713-7.

 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^

Highlights from the Fourth European Conference on AIDS
 by Gabriel Torres, M.D.

The Fourth European Conference on Clinical Aspects and 
Treatment of HIV Infection was held in Milan, Italy on March 
16-18, 1994 and was attended by over 2,000 delegates from 
Europe and the United States. The conference focused on 
clinical issues in the management of HIV infection and its 
complications rather than on basic or social sciences or 
epidemiology. Last month we highlighted conference reports on 
anti-HIV therapy. This month we give an account of the 
presentations concerning AIDS-related opportunistic 
infections.

New Diagnostic Techniques for Cytomegalovirus Infections

Various studies presented new methods for diagnosing CMV 
infections, especially those of the central nervous system. 
In one Swedish study,[1] 148 patients with encephalopathy had 
their cerebrospinal fluid examined with PCR for detection of 
viral genome (DNA). Diagnoses of herpes simplex, varicella 
zoster, Epstein Barr virus, JC virus (which causes PML) and 
CMV were made using this PCR technique in 39 to 42 percent of 
patients. One presentation[2] showed how CMV encephalitis could 
be diagnosed by detection of CMV DNA by in-situ hybridization 
from cerebrospinal fluid and cells. Another technique used by 
an Italian group[3] utilized a CMV pp65 antigen test as a blood 
or cerebrospinal fluid marker of active CMV infection in HIV-
positive patients with painful peripheral neuropathy. The 
development of these new diagnostic tests for CMV is crucial 
in making a prompt diagnosis of CMV encephalitis or 
neuropathy, which would otherwise require a brain or nerve 
biopsy.

Oral Ganciclovir To Prevent Cmv Retinitis Recurrence

A multicenter European-Australian study reported data 
comparing the use of oral and intravenous ganciclovir in 
preventing the recurrence of CMV retinitis.[4] Following 
induction with intravenous ganciclovir for two to three 
weeks, 159 patients were randomized to receive either oral 
ganciclovir (3 grams per day) or intravenous ganciclovir (5mg 
per kilogram of body weight once daily). Using photographic 
(fundoscopic) evaluation, the mean time to progression was 
109 days for the intravenous group and 86 days for the oral 
group. These results are not too different from those of the 
trials in the United States and confirm that the oral drug is 
almost as effective in delaying disease progression as the 
intravenous drug. It is certainly less toxic. 

Famciclovir for Herpes Zoster

A randomized placebo-controlled study found that 
famciclovir,[5] a new potent oral anti-herpes drug, was 
effective in the treatment of herpes zoster (shingles). Two 
doses of famciclovir (500 and 750mg) showed comparable 
efficacy and superiority over placebo in reducing the 
duration of virus recovery from zoster lesions as well as 
time to healing of lesions. A significant decrease in the 
duration of pain was detected for famciclovir-treated 
patients with severe rashes. The drug was well tolerated and 
had minimal side effects. A poster presentation reported that 
famciclovir also reduced the duration of post-herpetic 
neuralgia (pain which develops after the shingles have 
healed) from 128 days to 55 to 62 days.[6]

Toxoplasmosis Suppression

A randomized trial conducted by the ENTA Toxoplasmosis study 
group in France and Belgium[7] showed that the combination of 
pyrimethamine and clindamycin is clearly less effective for 
long term suppression of toxoplasmosis than the combination 
of sulfadiazine and pyrimethamine. Of 175 patients who had 
completed acute therapy for toxoplasmic encephalitis and who 
were randomized to one of the two suppressive regimens, 28 
percent relapsed on the clindamycin group compared to 7 
percent in the sulfadiazine group. A quarter of patients in 
each group had to discontinue therapy because of adverse 
effects, most commonly rashes in the sulfadiazine group and 
diarrhea in the clindamycin group. Other options for 
suppressive therapy of toxoplasmosis include atovaquone alone 
or in combination with pyrimethamine, azithromycin or 
rifabutin. 

European Tuberculosis Studies

A multicenter European study[8] testing a three-drug against a 
four-drug regimen for the treatment of tuberculosis in HIV-
infected patients was reported by a large consortium of 
researchers. The treatment regimen included isoniazid, 
rifampin, pyrazinamide with or without ethambutol.
Of the 611 patients under study, 475 had TB confirmed by 
culture. The treatment failure rate was similar in both 
groups, as was overall mortality. The level of TB resistance 
to more than one drug was low (6 percent). In this population 
of TB patients with low levels of drug resistance, the 
addition of ethambutol did not seem to be justified.

A Spanish tuberculosis study[9] described an outbreak of 
hospital acquired, multidrug resistant tuberculosis (MDRTB) 
at a facility in Madrid. Twenty cases of MDRTB were diagnosed 
between December 1992 and October 1993. The majority (85 
percent) of the patients died, 53 percent within the first 
month of diagnosis.

In a Rome hospital, 31 percent of the cases of TB were 
resistant to at least one drug.[10] Drug resistance was more 
common among patients with TB who had received previous anti-
TB therapy and had been noncompliant.

A blood test measuring adenosine deaminase (ADA) is being 
studied in Spain[11] for rapid diagnosis of tuberculosis and 
may prove useful in cases where there is a need to make an 
immediate treatment decision. Other rapid TB tests include 
PCR, the tuberculostearic acid assay and the luciferase gene 
detection method. 

Visceral Leishmaniasis

A relatively uncommon opportunistic infection in the United 
States was described by groups from three European countries 
(France, Spain and Italy). The disease, visceral 
leishmaniasis,[12] is caused by the Leishmania infantum 
protozoan which disseminates throughout the body and leads to 
high fever, liver and spleen enlargement and bone marrow 
disorders (leading to low red blood cell, neutrophil and 
platelet counts). The disease responds poorly to 
amphotericin, pentamidine or antimony drugs such as 
meglumine. Patients often relapse and the average survival is 
only 10.6 months. Resistance to meglumine was reported by one 
group of researchers in patients who had received several 
courses of the drug.[13] Immigrants from these European 
countries, as well as from Asia and South America who present 
with these symptoms should be evaluated for visceral 
leishmaniasis since it can be rapidly fatal if untreated. 

Terbinafine for Nail Fungal Infections

Toe nail fungal infections are very common in HIV-positive 
persons and may be the first sign of an impaired immune 
system. A British group reported that five of fifteen HIV-
positive patients with nail fungal infections caused by Tinea 
rubrum were successfully treated with a new antifungal drug 
called terbinafine.[14] Terbinafine is an allylamine antifungal 
agent that in the trial was given once daily at a dose of 
250mg for twelve weeks. The five patients who were cured did 
not relapse after 48 weeks of follow-up. But terbinafine was 
not effective in the treatment of oral thrush in another 
study reported at the conference.[15]

Aspergillus Infections Associated with Hospital Renovation

A cluster of thirteen cases of an invasive fungal infection 
called aspergillosis was reported by a group of Italian 
investigators.[16] The cases were associated with exposure of 
patients to the fungal spores in a hospital ward undergoing 
reconstruction. The cluster confirms the dangers of hospital 
acquired infections for AIDS patients during construction or 
renovation, which may release fungi such as Aspergillus 
fumigatus into the air.

Vitamin B12 and Folate Supplements

A group from Spain studied 75 patients with CD4 cell counts 
under 500 who were randomized to receive AZT (500mg per day) 
alone or in combination with folate (15mg per day) and 
vitamin B12 (1,000 micrograms per month, injected 
intramuscularly).[17] The study attempted to determine whether 
the vitamin supplements prevented AZT-related suppression of 
blood cell production in the bone marrow. After one year of 
follow-up, there were no differences in the hemoglobin, 
hematocrit, white blood cell, neutrophil or platelet counts 
between the two groups. The researchers concluded that these 
vitamins were not effective in preventing AZT-related 
hematological effects. Other studies have reported a 
beneficial effect of vitamin B12 in HIV-related peripheral 
neuropathy.

Zinc and Opportunistic Infections

A poster presentation reported on the use of zinc sulfate 
supplementation as preventive of opportunistic infections.[18] 
Thirty volunteers received 200mg of the supplement a day in 
combination with AZT and were compared to a group of eleven 
patients who received AZT alone. The frequency of 
opportunistic infections in the next two years was reduced in 
the group who received the zinc supplementation (nine 
infections versus 26 in the control group). The opportunistic 
infections in which zinc may have played a role included PCP, 
toxoplasmosis, cryptococcus, salmonella and tuberculosis; no 
effects were seen for CMV and esophageal candidiasis.

Clotting Disorders in HIV-Positive Patients

A French group reported 35 episodes of unprovoked thromboses 
(clots) among twenty patients in three hospitals.[19] Nineteen 
of the clots were in the deep leg veins, fourteen in the 
pulmonary vessels and two in cerebral vessels, leading to 
strokes. A deficiency of free protein S had been noted in a 
previous study of HIV-positive patients, and was recorded in 
six of eight of the patients who developed clots and had 
levels of Protein S measured. Protein S is involved in 
preventing spontaneous formation of clots, and a deficiency 
predisposes to thrombotic (clotting) episodes. It is unclear 
why some HIV-positive persons have protein S deficiency and 
are consequently at higher risk of unprovoked thrombotic 
episodes.

1 Cinque P, et al. abstract O20. Fourth European Conference 
on Clinical Aspects and Treatment of HIV Infecton, 1994.

2 Manicardi G, et al. abstract P138.

3 Volpi A, et al. abstract P137.

4 Knopse V, et al. abstract O21.

5 Tyring S, et al. abstract O24.

6 Tyring S, et al. abstract P159.

7 de Wit S, et al.; abstract P192.

8 European Tuberculosis Study Group. abstract O54.

9 Moreno V, et al. abstract 355.

10 Palmieri F, et al. abstract 356.

11 Fernndez-Gonzlez F, et al. abstract 360.

12 Rosenthal E, et al. abstract O27.

13 Gambarelli F, et al. abstract O28.

14 Nandwani R, et al. abstract P233.

15 Cartledge JD, et al. abstract O31.

16 Libanore M, et al. abstract P234.

17 Falguera M, et al. abstract P264.

18 Mocchegiani E, et al. abstract 306.

19 Pulik M, et al. abstract O62.

 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^

Drug company watch 
 by David Gold and Dave Gilden

SmithKline Blocks Investigation of AIDS Drug

Alan Pardee, M.D., and his group at Harvard University's 
Dana-Farber Institute has found that the experimental 
anticancer drug topotecan is also a potent inhibitor in the 
test tube of HIV replication. General rights to topotecan are 
owned by its manufacturer, SmithKline Beecham, but Dana-
Farber proceeded to file a use patent for HIV applications. 
SmithKline in response has stopped supplying topotecan for 
any HIV experimentation and refuses to negotiate any payment 
to Dana-Farber. One prominent researcher is said to have been 
ready to begin a trial using topotecan in HIV-positive people 
with lymphoma, but SmithKline delayed it at the last moment. 
The company reportedly now insists that all future topotecan 
trials for whatever purpose exclude anyone who tests HIV-
positive.

First Human Data on Effectiveness of Antisense Drugs

Isis Pharmaceuticals of San Diego is reporting encouraging 
preliminary data on its antisense compound aimed at CMV, 
blocking a gene necessary for the virus's reproduction. The 
drug, ISIS 2922, is injected weekly into the patients' eyes 
to arrest CMV retinitis. CMV-associated retinal lesions 
resolved (leaving inactive patches) in all five members of 
the ISIS 2922 trial's high-dose arm. The same happened to two 
of three volunteers receiving the medium dose. There have 
been no relapses so far in up to four months of treatment. 
All these patients had failed or become intolerant of the 
standard CMV therapies, ganciclovir and foscarnet. Despite 
these positive results (which were publicized by the 
company's PR department), Isis insists that it is premature 
to begin a compassionate use program for people outside of 
the Isis trials who are doing poorly on the approved CMV 
retinitis medications.

First U.S. HIV Antisense Trial Starts

Hybridon, a Worcester, Massachusetts based biotechnology 
company, received FDA approval to test its antisense product, 
GEM-91, which disrupts a sequence on the HIV gag gene 
essential for constructing the core of new virus particles. 
Trials are to begin by the end of April at the University of 
Alabama and will include six HIV-positive patients. Michael 
Saag is the principal investigator. GEM-91 is administered 
intravenously. The drug has been studied in 23 patients in 
France without side effects. However, in primates, serious 
cardiovascular side effects were seen. In test tubes, GEM-91 
inhibits HIV replication.

Bristol Meets with Activists on d4T 

Officials from Bristol-Myers Squibb met with activists to 
discuss the company's new drug application for d4T. Bristol 
officials suggested that the company's AIDS drug development 
program would be negatively affected if community 
representatives did not support FDA approval of the drug. By 
the end of the year, the company will release results from a 
trial comparing d4T and AZT in 813 patients with at least six 
months of previous AZT therapy. Bristol also is commencing a 
d4T/ddI combination trial, even though the combination 
enhances the risk of peripheral neuropathy.

Viagene Begins New Gene Therapy Trial

A 20-person trial of Viagene's HIV gene therapy product has 
begun in HIV-infected individuals with CD4 counts between 200 
and 500 at the University of California San Diego. 
Participants will receive three injections over six weeks. 
The injections contain the participants' own cells 
genetically altered to express HIV protein on their surfaces. 
It is hoped these cells will stimulate immune system 
cytotoxic "killer cells" to attack HIV-containing cells. An 
ongoing study is following the therapy in HIV-positive 
patients with over 500 CD4 cells. Green Cross, a Japanese 
company has agreed to continue funding development of this 
immune therapy through 1996.

Lilly Leaves HIV Research

The Eli Lilly Corporation has announced that it is 
discontinuing its HIV research. The company is in the midst 
of restructuring its clinical program. Lilly had worked with 
Agouron in developing the company's protease inhibitor.

Price Competition for Acyclovir (Zovirax)

SmithKline's famciclovir received approval as a treatment for 
shingles (herpes zoster) in England. The drug is priced about 
eight percent less than acyclovir. Most people expect that 
the U.S. will approve famciclovir in the near future. 
Approval will mean greater price competition for zovirax, it 
is hoped.

 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^
 ^^^^^^^^^^^^^^^^^^^^^^^^^^^^

Treatment Briefs 
 by David Gold

Oral Ganciclovir Access Plan (Sort of)

The Syntex Corp. of Palo Alto, California has announced a 
program to make oral ganciclovir available to PWAs with CMV 
who are unable to receive ganciclovir through central 
catheter due to catheter infections or thrombosis (clotting 
of veins). Physicians should call 800/569-4630. Activists 
criticized the open label program because of the amount of 
time it took to develop and, more importantly, because it 
requires that patients must have a history of having a 
catheter removed two or more times due to catheter infection 
or thrombosis within the six months prior to enrollment. 
Kevin Frost of ACT UP and TAG called the program "laughable." 
Syntex plans to meet with community representatives to 
"discuss these issues."

Hyperthermia Trial to Start

The FDA has allowed a six-patient trial of hyperthermia as a 
treatment for Kaposi's sarcoma in people with AIDS. Dr. 
Kenneth Alonso, who conducted hyperthermia on a number of 
patients, will be overseeing the trial. 

Dr. Alonso's hyperthermia procedure involves withdrawing 
blood from the patient, then heating it to 110 degrees 
Fahrenheit and returning the blood to the patient. 
Hyperthermia attracted widespread attention in 1990 when a 
few patients with AIDS claimed a "remission" after undergoing 
the procedure. Some individuals were reportedly charged 
upwards of $30,000 for the treatment. At the time, the 
National Institutes of Health stated that it found no benefit 
to hyperthermia therapy. Concerns about hyperthermia include 
the fact that a significant number of patients died from the 
procedure (seven percent in one trial) as well as the 
procedure's high price. In addition, it is unlikely that 
removing blood and "treating" it will affect the lymph 
system, where much of the early HIV replication occurs.
Nevertheless, Biocontrol, a Pittsburgh-based company, is 
developing the hyperthermia procedure. The company claims 
that "favorable results" were seen from the hyperthermia 
procedure on KS patients. 

In what is no doubt a bit of an understatement, Senator Frank 
Lautenberg (D-New Jersey), who pushed the FDA to allow the 
trial to proceed, suggested "we are far from announcing a 
cure for AIDS."

Pentoxifylline: Disappointing Data and a Warning

Pentoxifylline (also called trental) is an approved treatment 
for a circulation disorder caused by a narrowing of the 
arteries. The drug is also being used by HIV-infected people 
based on preliminary data that suggests it reduces tumor 
necrosis factor (TNF), an immune system protein that may 
increase HIV replication and contribute to wasting syndrome. 
However, a three week study by researchers from the Veteran's 
Administration Medical Center in Palo Alto, California 
reported that pentoxifylline produced no immediate benefits 
in terms of CD4 counts, viral load or clinical status (May 
1994; Journal of AIDS; 7:5(5)19-20). In addition, significant 
side effects were seen at the dose given (2,400mg per day). 
Of nine HIV-positive patients (CD4 count less than 400) given 
the drug, one patient had to be reduced to 1,200mg per day 
and three others could not tolerate the drug at either dose. 
Reported side effects included fevers, gastrointestinal 
upset, headaches, and nausea. No antiretroviral therapy (AZT, 
ddI or ddC) was given.

The six remaining patients were followed for three weeks of 
therapy. Viral load (as measured by HIV plasma RNA and p24 
antigen) did not change in five of six patients. In addition, 
no overall effects on TNF levels were seen. 

In a reply to the published results, Dr. Bruce Dezube, a 
researcher from Beth Israel Hospital in Boston who has done 
extensive studies of pentoxifylline, noted that 
antiretroviral therapy such as AZT was not included in the 
study regimen. Dr. Dezube believes that if pentoxifylline is 
to play a role in the overall treatment of HIV disease, it 
will be in combination with an antiretroviral agent. 
The VA study comes on the heels of a request by the BGA, 
Germany's drug regulatory agency, that doctors report any 
changes in the retina in patients treated with 
pentoxifylline. According to Scrip, a drug industry 
newsletter, the advisory was issued because a patient on 
pentoxifylline developed retina bleeding and detachment. The 
BGA emphasized that no causal relationship has been 
established between the drug and retinal disorders. 
Pentoxifylline is known to cause bleeding of the skin, 
mucosal areas and stomach.

Hydrogen Peroxide Therapy

Treatment Issues has received a number of questions regarding 
the use of hydrogen peroxide as a therapy for HIV. There is 
no evidence that injecting hydrogen peroxide will provide any 
benefit for HIV disease and there is some evidence that it is 
quite dangerous. A recent letter in the Annals of Internal 
Medicine (April 15, 1994;120: 694) reported the death of a 
PWA who injected hydrogen peroxide into his catheter. He 
subsequently developed nausea, dark urine, and a rapid heart 
beat. Kidney problems soon developed and the patient died 
five days after injecting the hydrogen peroxide.

Poppers and the Immune System

Isobutyl nitrite inhalers or "poppers" can reduce the 
functional ability of T-cells in mice, according to a 
researcher from the University of Arkansas (Toxicology 
Letters, February 15, 1994; 70:319-29). Mice in the study 
were exposed to three doses of isobutyl nitrite (900 parts 
per million, 600 ppm and 300 ppm) for 45 minutes a day for 
fourteen days. By comparison, one of the leading "popper" 
products, "Probe," releases over 1,500 ppm of isobutyl 
nitrate.

The study found that mice given the two higher doses had T-
cell mediated responses that were reduced by 37 percent. 
However, three days after the last exposure to isobutyl 
nitrate, T-cell functions returned to normal. In a 
conversation with Treatment Issues, the lead investigator of 
the study, Dr. Lee Soderberg, concluded that the reduction in 
T-cell functioning in mice after exposure to isobutyl nitrate 
was statistically significant, but reversible. He also noted 
that the mice exposed to isobutyl nitrate showed reduced 
tumor killing capabilities which returned to normal levels 
more slowly than T-cell functioning. 

New Drug Tested for Genital Warts

A topical formulation of HPMPC, an anti-CMV drug being 
developed by Gilead Sciences, is now being studied as a 
treatment for anal and genital warts in HIV-infected 
patients. The trial is ongoing at three sites: the Conant 
Medical Group, the University of Washington at Seattle, and 
the Houston Clinical Research Network. 

An intravenous (IV) version of HPMPC is now in phase II/III 
trials for CMV. The drug is believed to work against strains 
of human papilloma virus (HPV) which are associated with 
genital warts. HPV has been linked to increased rates of 
cervical cancer in HIV-positive women and anal cancer in gay 
and bisexual HIV-positive men. The topical formulation of 
HPMPC is being administered once a day. It is also being 
studied in acyclovir-resistant herpes. 

According to Dr. Conant's office, early indications from the 
study for genital warts are "promising." In the first three 
patients treated (all with anal warts), one patient had a 
complete clearing, one had "extensive reduction," and one had 
a self-described 50 percent reduction in warts per day. It 
should be noted, however, that genital warts clear 
spontaneously in about 25 percent of cases when a placebo is 
given. Nevertheless, HPMPC is the first therapy tested 
against HPV that attacks the virus itself and, according to 
the company, protects uninfected cells against HPV. 

Depression and HIV

Two studies on depression and disease progression among HIV-
positive individuals were recently published in The Journal 
of the American Medical Association (JAMA, 1993; 270: 2563-
74).

One group of researchers, Lyketsos, et al. from the 
Multicenter AIDS Cohort Study (MACS), found that depression 
was not associated with increased disease progression or 
death. However, another study, published in the same edition, 
by Burack, et al. from San Francisco General Hospital, 
concluded that "depression predicted a more rapid decline" in 
CD4 counts. The first study, which did not find an 
association, was significantly larger than the second. It 
measured not only CD4 counts but "at least five assessments" 
of disease progression. An editorial entitled "Depression and 
HIV: How Does One Affect the Other?" accompanied the two 
reports. It noted, "We are reminded by both studies that most 
HIV-infected subjects are not depressed."

The editorial continued, "We continue to urge clinicians to 
view depression in this population as a psychopathological 
condition warranting treatment to reduce suffering and to 
improve functioning. But we also recommend that clinicians be 
cautious in suggesting that HIV-infected patients should 
reduce their depression because of its direct effects on 
their T-cells. Such a stance is not well substantiated and 
may foster self-accusation when disease progression occurs." 

Correction

March's edition of Treatment Issues incorrectly stated that 
the on-going trial of Abbott Laboratories lead protease 
inhibitor, A-84538, required participants to visit the clinic 
every day for their daily dose. Actually, trial participants 
will receive a cooler to transport their supply of the drug, 
which comes in pill form and has to be stored at temperatures 
below freezing. Other conditions for entering the trial 
remain restrictive: Participants must have no opportunistic 
infections and forego all other medications except for 
prophylaxis for pneumocystis carinii pneumonia. They also 
must have a CD4 count of more than 50. These criteria exclude 
most people at the low end of the CD4 range. Volunteers also 
must have substantial HIV levels in their blood, as measured 
by the branched-chain DNA assay. This requirement excludes 
many people with higher CD4 counts - a CD4 count of up to 
500 is allowable in the trial.
                            
